Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > Pfizer and Flynn Pharma still in Business
View:
Post by jimmyjong on Jun 13, 2016 3:53pm

Pfizer and Flynn Pharma still in Business

Ann Pope, CMA Senior Director of Antitrust Enforcement, said:

While businesses are generally free to set prices as they see fit, those that hold a dominant position have a special responsibility to ensure that their conduct does not impair genuine competition and that their prices are not excessive and unfair. The prices that the CMA is concerned about in this case are very high compared to those prices previously charged and have led to a big increase in the total NHS drug bill for what is a very important drug for tens of thousands of patients.

The CMA’s findings on dominance and abuse are provisional and no conclusion can be drawn at this stage that there has, in fact, been any breach of competition law. We will carefully consider any representations from Pfizer and Flynn Pharma before deciding whether the law has been infringed.
 

CMA opens investigation into discounting in the pharmaceutical sector

On 2 December 2015, the UK Competition and Markets Authority (“CMA”) announced the opening of a new investigation in the pharmaceutical sector. The investigation is focussed on whether an unnamed company has abused a dominant market position through discounting of its pharmaceutical products.  
 
There are no further details publicly available on the identity of the company under investigation or the product concerned. The CMA has set a deadline of May 2016 to decide whether to proceed with the investigation.

 
 
Comment by sunshine7 on Jun 13, 2016 4:05pm
ok, so they also investigate prices that are too low. So by logical extension, high prices encourages competition. So what's the problem?
Comment by Marcel7 on Jun 13, 2016 4:18pm
The case you are quoting at the bottom is unlikely to have anything to do with AMCo, but I agree with your overall assertion. Pfizer and Flynn are still in business. It takes years for these cases to play out, even to decide IF to continue with the investigation can take years. By that time CXR will have paid off a significant chunk of debt and would be able to pay out any likely fines with cash ...more  
Comment by yycish1027 on Jun 13, 2016 4:28pm
Great reading and thanks for great info. I would like to add on something as well. The investigation and fines and so forth used by the regulatory body are there to ensure compliance. The intention here is "healthy comptition environment", not a mission of taking company down. "The big brother is still watching" is the message in this case 1027
Comment by yycish1027 on Jun 13, 2016 4:29pm
Great reading and thanks for great info. I would like to add on something as well. The investigation and fines and so forth used by the regulatory body are there to ensure compliance. The intention here is "healthy comptition environment", not a mission of taking company down. "The big brother is still watching" is the message in this case 1027
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities